<DOC>
	<DOCNO>NCT00410384</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , tolerability , impact quality life two different dos belimumab administer addition standard therapy subject active , autoantibody-positive systemic lupus erythematosus ( SLE ) disease .</brief_summary>
	<brief_title>A Study Belimumab Subjects With Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Key Clinical diagnosis SLE ACR criterion . Active SLE disease . Autoantibodypositive . On stable SLE treatment regimen . Key Pregnant nursing Have receive treatment B cell target therapy . Have receive treatment biological investigational agent past year . Have receive IV cyclophosphamide within 180 day Day 0 . Have severe lupus kidney disease . Have active central nervous system ( CNS ) lupus . Have require management acute chronic infection within past 60 day . Have current drug alcohol abuse dependence . Have historically positive test test positive screening HIV , hepatitis B , hepatitis C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Antibodies</keyword>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>SLE</keyword>
	<keyword>Belimumab</keyword>
	<keyword>Lupus</keyword>
</DOC>